Effects of Denosumab vs Alendronate on Bone Mineral Density (BMD), Bone Turnover Markers (BTM), and Safety in Women Previously Treated with Alendronate.

被引：0
|
作者：
Kendler, D. L. [1 ]
Benhamou, C. L. [2 ]
Brown, J. P. [3 ]
Lillestol, M. [4 ]
Roux, C. [5 ]
Man, H. S. [6 ]
Siddhanti, S. [6 ]
Martin, J. San [6 ]
Bone, H. G. [7 ]
机构：
[1] Clin Res Ctr, Vancouver, BC, Canada
[2] Ctr Hosp, Orleans, France
[3] Univ Laval, CHUQ, Quebec City, PQ, Canada
[4] Internal Med Associates, Fargo, ND USA
[5] Hop Cochin, F-75674 Paris, France
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
[7] Michigan Bone & Mineral Clin, Detroit, MI USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2008年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S473 / S473
页数：1
相关论文
共 50 条
  • [1] Early Effects of Denosumab in Postmenopausal Women with Low Bone Mineral Density Previously Treated with Alendronate
    Brown, J. P.
    Kendler, D. L.
    Benhamou, C. L.
    Lillestol, M.
    Roux, C.
    Siddhanti, S.
    Man, H. S.
    Martin, J. San
    Bone, H. G.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 3973 - 3974
  • [2] ASSESSMENT OF BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN TRANSITIONED FROM ALENDRONATE TO DENOSUMAB
    Roux, C.
    Brown, J. P.
    Kendler, D. L.
    Lillestol, M.
    Siddhanti, S.
    Man, H. S.
    Martin, J. San
    Bone, H. G.
    Benhamou, C. L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 10 - 11
  • [3] RELATIONSHIP BETWEEN REDUCTION IN BONE TURNOVER MARKERS (BTM) AND CHANGE IN BONE MINERAL DENSITY (BMD) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED WITH DENOSUMAB
    Eastell, R.
    Christiansen, C.
    Grauer, A.
    Kutilek, S.
    Libanati, C.
    McClung, M.
    Resch, H.
    Siris, E.
    Uebelhart, D.
    Reid, I.
    Wang, A.
    Weryha, G.
    Cummings, S.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 185 - 186
  • [4] Evolution of bone mineral density and bone turnover in osteoporotic women shifting from pamidronate to alendronate.
    Peretz, AME
    Siderova, V
    Body, J
    Dumon, J
    Fellemans, C
    Fuss, M
    Rozenberg, S
    Bergmann, P
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S527 - S527
  • [5] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
    Kendler, David L.
    Roux, Christian
    Benhamou, Claude Laurent
    Brown, Jacques P.
    Lillestol, Michael
    Siddhanti, Suresh
    Man, Hoi-Shen
    Martin, Javier San
    Bone, Henry G.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) : 72 - 81
  • [6] Effects of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
    Johnell, O
    Lu, Y
    Seeman, E
    Reginster, J
    Scheele, W
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S184 - S184
  • [7] Effect of Denosumab vs Alendronate on Bone Turnover Markers and Bone Mineral Density Changes at 12 Months Based on Baseline Bone Turnover Level
    Brown, J. P.
    Deal, C.
    de Gregorio, L. H.
    Hofbauer, L. C.
    Wang, H.
    Austin, M.
    Wagman, R. B.
    Newmark, R.
    Libanati, C.
    Martin, J. San
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2590 - 2591
  • [8] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Atmaca, Aysegul
    Gedlik, Olcay
    [J]. ADVANCES IN THERAPY, 2006, 23 (06) : 842 - 853
  • [9] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Aysegul Atmaca
    Olcay Gedik
    [J]. Advances in Therapy, 2006, 23 : 842 - 853
  • [10] CHANGE IN BONE MINERAL DENSITY (BMD) OR BONE TURNOVER MARKERS (BTM) DID NOT PREDICT RISK OF VERTEBRAL FRACTURE AFTER DISCONTINUATION OF ALENDRONATE IN THE FLEX STUDY
    Chang, S.
    Bauer, D.
    Black, D.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S377 - S377
12345